January 1, 1985Clinical and Experimental Hypertension
Effect of Atrial Natriuretic Factor ANF (arg 101–Tyr 126) on Kallikrein and Cyclic GMP in the Renovascular Hypertensive Rat
Why the study?
Does synthetic ANF reduce blood pressure and alter kallikrein and cGMP levels in renovascular hypertensive rats?
Population
Renovascular hypertensive rats and normotensive controls
Comparison
Intravenous injection of an ED50 natriuretic… vs Normotensive sham-operated rats and…
Design
Preclinical
Follow-up
acute (greater than 40 min)
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for synthetic ANF in renovascular hypertension; prospective human studies needed before clinical adoption.
Structured PICO
Does synthetic ANF reduce blood pressure and alter kallikrein and cGMP levels in renovascular hypertensive rats?
P
Population
Renovascular hypertensive rats (2-K, 1-C and 1-K, 1-C models) and normotensive controls (sham-operated and uninephrectomized)
I
Intervention
Intravenous injection of an ED50 natriuretic dose (1 microgram) of synthetic ANF [ANF (arg 101–Tyr 126)]
C
Comparator
Normotensive sham-operated rats and uninephrectomized normotensive controls
O
Outcome
Blood pressure reductionsurrogate
Synthetic ANF induces significant hypotension and diuresis in renovascular hypertensive rats, potentially mediated by vasodilation.
Cite This Study
García et al. (1985) studied this question.